US team develops prognostic gene chip for neuroblastoma:
This article was originally published in Clinica
Executive Summary
US researchers have developed a DNA chip that could help predict outcomes for infants with neuroblastoma, a common form of cancer in children less than 10 years of age. The chip can be configured to identify selected genetic abnormalities and deletions in isolated regions of chromosome 11, which is believed to allow aggressive neuroblastoma to take hold. Investigators from The Children's Hospital of Philadelphia and Thomas Jefferson University said that the chip could also be modified to help identify other forms of cancer. Their proof-of-principle study featured in the August edition of Genome Research. The team is currently seeking industry support to help improve the technology.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.